ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Amlodipine

Also written as “amlodipine”, “Amlodipine 5 mg” and “Amlodipine 10 mg”.

Its studies are mostly in Hypertension · Essential Hypertension · Hyperlipidemias · Kidney Diseases · Hypercholesterolemia, led by 35 companies.

Drug pageAmlodipine: every studyMany companies study it; this page follows only the 170 they lead. All 284 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 25, 2005170 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only570 open or runningphase 4since Aug 25, 2005Aug 25, 2005none ahead
Boehringer Ingelheim220 open or runningphase 4since Oct 14, 2005Oct 14, 2005none ahead
Viatrisits history only130 open or runningphase 4since Aug 31, 2005Aug 31, 2005none ahead
Hanmi Pharmaceuticalits history only110 open or runningphase 3since Jul 14, 2009Jul 14, 2009none ahead
Dr. Reddy's Laboratoriesits history only80 open or runningphase 1since May 26, 2010May 26, 2010none ahead
HK inno.Nits history only50 open or runningphase 3since Feb 16, 2015Feb 10, 2014none ahead
Handokits history only40 open or runningphase 3since Jul 24, 2022Jul 21, 2020none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Feb 9, 2009Feb 9, 2009none ahead
Yuhanits history only41 open or runningphase 4since Sep 4, 2023May 29, 2014none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 3since Jan 8, 2016Feb 14, 2014none ahead

Also a collaborator on its studies: CSPC Pharmaceutical Group and Integrium.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boehringer Ingelheim only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Oct 14, 2005.

  1. Jan 24, 2006Phase 3 study in HypertensionNCT00281580 · 1,461 enrolled · United States, Argentina, Brazil and more
  2. Oct 8, 20074 phase 3 studies in HypertensionNCT00553267, NCT00550953, NCT00558428 and 1 more
  3. Jan 28, 2008Phase 3 study in HypertensionNCT00614380 · 976 enrolled · Belgium, Canada, Denmark and more
  4. Feb 5, 2008Phase 3 study in HypertensionNCT00624052 · 838 enrolled · Australia, Austria, Bulgaria and more
  5. Mar 11, 2009Phase 3 study in HypertensionNCT00860262 · 858 enrolled · United States, Bulgaria, Czech Republic and more
  6. Apr 13, 2010Phase 3 study in HypertensionNCT01103960 · 324 enrolled · China, Malaysia, Philippines
  7. May 28, 2010Phase 3 study in HypertensionNCT01134393 · 502 enrolled · Germany, Italy, Mexico and more
  8. Aug 10, 2010Phase 1 study in HealthyNCT01181011 · 28 enrolled · China
  9. Sep 16, 2010Phase 3 study in HypertensionNCT01204398 · 27 enrolled · China
  10. Oct 15, 2010Phase 3 study in HypertensionNCT01222520 · 174 enrolled · Japan
  11. Jan 17, 2011Phase 1 study in HypertensionNCT01278797 · 28 enrolled · Canada
  12. Jul 26, 2013Phase 3 study in HypertensionNCT01911780 · 132 enrolled · Japan
  13. Jul 7, 20142 phase 1 studies in HealthyNCT02183675, NCT02193308
  14. Oct 6, 20143 phase 1 studies in HealthyNCT02259829, NCT02259816, NCT02261064

TargetBeta

“Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
PregabalinruleViatrisphase 4149
GabapentinruleViatrisphase 449
DronedaroneruleSanofiphase 418
NifedipineruleBayerphase 418

Studies

All 22 Boehringer Ingelheim leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02261064Healthy1CompletedFeb 200932
NCT02259829Healthy1CompletedNov 200784
NCT02259816Healthy1CompletedAug 200638
NCT02193308Healthy1CompletedNov 200784
NCT02183675Healthy · Japan1CompletedOct 201436
NCT01911780Hypertension · Japan3CompletedJan 2015132
NCT01278797Hypertension · Canada1CompletedFeb 201128
NCT01222520Hypertension · Japan3CompletedJun 2011174
NCT01204398Hypertension · China3CompletedJul 201127
NCT01181011Healthy · China1CompletedNov 201028
NCT01134393Hypertension · Germany, Italy, Mexico and more3CompletedMay 2011502
NCT01103960Hypertension · China, Malaysia, Philippines3CompletedAug 2011324
NCT00860262Hypertension · United States, Bulgaria, Czech Republic and more3CompletedDec 2009858
NCT00624052Hypertension · Australia, Austria, Bulgaria and more3CompletedJun 2009838
NCT00614380Hypertension · Belgium, Canada, Denmark and more3CompletedMar 2009976
NCT00558428Hypertension · Belgium, Canada, Denmark and more3CompletedSep 20081,098
NCT00558064Hypertension · Japan3CompletedSep 2008531
NCT00550953Hypertension · Japan3CompletedJul 2008314
NCT00553267Hypertension · Australia, Austria, Bulgaria and more3CompletedOct 2008947
NCT00281580Hypertension · United States, Argentina, Brazil and more3CompletedMar 20071,461
NCT00242814Hypertension · France4CompletedMar 29, 2007100
NCT00240474Hypertension · Belgium, Denmark, Finland and more4CompletedMar 20041,000

How it is read

Names in the registry

  • “Amlodipine”, 44 entries
  • “amlodipine”, 14 entries
  • “Amlodipine 5 mg”, 9 entries
  • “Amlodipine 10 mg”, 6 entries
  • “valsartan + amlodipine”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.